Bavituximab Biosimilar – Anti-Phosphatidylserine mAb – Research Grade

Description of Bavituximab Biosimilar - Anti-Phosphatidylserine mAb - Research Grade

Bavituximab Biosimilar – A Next-Generation Antibody for Targeting Phosphatidylserine Introduction

Bavituximab Biosimilar is a novel monoclonal antibody (mAb) that has been developed as a biosimilar to the therapeutic antibody bavituximab. It specifically targets phosphatidylserine (PS), a phospholipid that is found on the inner leaflet of the cell membrane. PS is known to play a crucial role in a variety of biological processes, including cell signaling, cell survival, and immune regulation. The unique ability of Bavituximab Biosimilar to bind to PS makes it a promising therapeutic candidate for a range of diseases.

Structure of Bavituximab Biosimilar

Bavituximab Biosimilar is a recombinant, humanized mAb that has been engineered using state-of-the-art technology. It is a chimeric antibody, meaning that it contains both human and non-human components. The antibody is composed of two heavy chains and two light chains, each with a variable region that specifically binds to PS. The constant region of the antibody is derived from human immunoglobulin G (IgG), which provides stability and effector functions.

Mechanism of Action

Bavituximab Biosimilar works by binding to PS on the surface of cells, leading to the activation of the body’s immune system. PS is normally present on the inner leaflet of the cell membrane, but in diseased cells, it can be exposed on the outer surface. This exposure of PS is a hallmark of many diseases, including cancer, viral infections, and autoimmune disorders. By targeting PS, Bavituximab Biosimilar can selectively bind to diseased cells and trigger an immune response, leading to their destruction.

Therapeutic Applications

Bavituximab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various diseases. Its ability to specifically target PS makes it a potential therapeutic option for a range of conditions, including cancer, infectious diseases, and autoimmune disorders.

Cancer

In cancer, PS is exposed on the surface of tumor cells, making them an ideal target for Bavituximab Biosimilar. The antibody has been shown to induce tumor cell death and inhibit tumor growth in various types of cancer, including lung, breast, and pancreatic cancer. It has also been found to enhance the effects of chemotherapy and radiation therapy, making it a potential combination therapy option.

Infectious Diseases

Bavituximab Biosimilar has also shown promising results in the treatment of viral infections, including hepatitis C and Ebola. PS is exposed on the surface of infected cells, and by binding to it, Bavituximab Biosimilar can enhance the body’s immune response and help in the clearance of the virus. This mechanism of action has the potential to be effective against a wide range of viral infections.

Autoimmune Disorders

In autoimmune disorders, the body’s immune system mistakenly attacks its own cells and tissues. By targeting PS, Bavituximab Biosimilar can modulate the immune response and restore immune tolerance, making it a potential treatment option for diseases such as rheumatoid arthritis and multiple sclerosis.

Research Grade Availability

Bavituximab Biosimilar is currently available in research grade for use in preclinical studies. The antibody is produced using advanced cell culture techniques and has been extensively characterized for its purity, stability, and specificity. Its availability in research grade allows for further investigation of its therapeutic potential in various diseases and lays the foundation for its future clinical development.

Conclusion

Bavituximab Biosimilar is a next-generation antibody that specifically targets PS, a phospholipid that is exposed on the surface of diseased cells. Its unique mechanism of action and potential therapeutic applications make it a promising candidate for the treatment of various diseases. With its availability in research grade, further studies

SDS-PAGE for Bavituximab Biosimilar - Anti-Phosphatidylserine mAb

Bavituximab Biosimilar - Anti-Phosphatidylserine mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.